Serum albumin and lipoproteins

Serum albumin and lipoproteins are the primary transport vehicles in human plasma, essential for maintaining physiological homeostasis and determining the pharmacokinetic profiles of numerous drugs [UniProt P02768, StatPearls: Physiology, Albumin]. Serum albumin is a 66 kDa monomeric protein that maintains oncotic pressure and binds a diverse range of ligands, including fatty acids, bilirubin, and acidic drugs like warfarin [StatPearls: Physiology, Albumin, PubMed: 20103010]. Lipoproteins, categorized by density (e.g., LDL, HDL, VLDL), are complex particles that transport hydrophobic lipids such as cholesterol and triglycerides through the circulatory system [StatPearls: Lipoprotein Metabolism]. While albumin itself is used therapeutically for volume expansion, lipoproteins are central to the management of cardiovascular diseases, where drugs like statins and PCSK9 inhibitors modulate their levels to prevent atherosclerosis [NIH: High Blood Cholesterol]. Because this entry combines a specific protein with a broad class of lipid-protein complexes, it is typically treated as two distinct pharmacological entities rather than a single therapeutic target. The interaction between drugs and these molecules is a critical factor in drug development, as it influences the volume of distribution and the rate of clearance. Pathological states such as liver cirrhosis or nephrotic syndrome can significantly alter the levels of these proteins, leading to impaired drug transport and increased risk of toxicity. Monitoring these levels is standard clinical practice for assessing nutritional status, liver function, and cardiovascular risk.

Other names

Plasma transport proteinsBlood proteinsAlbumin and Lipoprotein particlesPlasma protein binding components

Albumin acts as a carrier protein that binds drugs at specific sites (e.g., Sudlow's sites), affecting their free concentration and distribution [PubMed: 20103010]. Lipoproteins are modulated by drugs that inhibit cholesterol synthesis (e.g., statins) or increase receptor-mediated clearance (e.g., PCSK9 inhibitors) to reduce circulating lipid levels [StatPearls: Lipoprotein Metabolism, NIH: High Blood Cholesterol].